Shanghai Pharmaceuticals duloxetine hydrochloride enteric-coated tablets passed the consistency evaluation of generic drugs

On June 7th, Shanghai Pharmaceuticals issued an announcement stating that recently, its holding subsidiary Shanghai Shanghai Pharmaceuticals Zhongxi Pharmaceutical Co.
, Ltd.
(hereinafter referred to as “Shanghai Pharmaceuticals Zhongxi”) has received the relevant duloxetine hydrochloride enteric-coated tablets issued by the State Food and Drug Administration.
The “Notice of Approval of Supplementary Application for Drugs” (notice number: 2021B01547), the drug passed the quality and efficacy consistency evaluation of generic drugs
.

Duloxetine hydrochloride enteric-coated tablets are mainly used for the treatment of depression, originally developed as capsules, developed by Lilly, and launched in the United States in 2004
.

As of this announcement, the drug manufacturers in China only on Chinese and Western medicine Shanghai Pharmaceutical Co.
, Ltd.
and Jiangsu En Hua Pharmaceutical Co.
, Ltd.
two companies
.